Literature DB >> 29332257

Kynurenic acid and its derivatives are able to modulate the adhesion and locomotion of brain endothelial cells.

Eszter Lajkó1, Bernadett Tuka2, Ferenc Fülöp3,4, István Krizbai5, József Toldi2,6, Kálmán Magyar7, László Vécsei2,8, László Kőhidai9.   

Abstract

The neuroprotective actions of kynurenic acid (KYNA) and its derivatives in several neurodegenerative disorders [characterized by damage to the cerebral endothelium and to the blood-brain barrier (BBB)] are well established. Cell-extracellular matrix (ECM) adhesion is supposedly involved in recovery of impaired cerebral endothelium integrity (endothelial repair). The present work aimed to investigate the effects of KYNA and its synthetic derivatives on cellular behaviour (e.g. adhesion and locomotion) and on morphology of the GP8 rat brain endothelial cell line, modeling the BBB endothelium. The effects of KYNA and its derivatives on cell adhesion were measured using an impedance-based technique, the xCELLigence SP system. Holographic microscopy (Holomonitor™ M4) was used to analyse both chemokinetic responses and morphometry. The GP8 cells proved to be a suitable model cell line for investigating cell adhesion and the locomotion modulator effects of kynurenines. KYNA enhanced cell adhesion and spreading, and also decreased the migration/motility of GP8 cells at physiological concentrations (10-9 and 10-7 mol/L). The derivatives containing an amide side-chain at the C2 position (KYNA-A1 and A2) had lower adhesion inducer effects compared to KYNA. All synthetic analogues (except KYNA-A5) had a time-dependent inhibitory effect on GP8 cell adhesion at a supraphysiological concentration (10-3 mol/L). The immobilization promoting effect of KYNA and the adhesion inducer activity of its derivatives indicate that these compounds could contribute to maintaining or restoring the protective function of brain endothelium; they also suggest that cell-ECM adhesion and related cell responses (e.g. migration/motility) could be potential new targets of KYNA.

Entities:  

Keywords:  Brain endothelial cell; Endothelial repair; Holographic microscopy; Impedimetry; Kynurenic acid; Kynurenic acid (PubChem CID: 3845); L-Kynurenine (Pubchem CID: 161166); Synthetic kynurenines

Mesh:

Substances:

Year:  2018        PMID: 29332257     DOI: 10.1007/s00702-018-1839-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  59 in total

Review 1.  Vascular repair by endothelial progenitor cells.

Authors:  Anna Zampetaki; John Paul Kirton; Qingbo Xu
Journal:  Cardiovasc Res       Date:  2008-03-18       Impact factor: 10.787

2.  Kynurenic acid has a dual action on AMPA receptor responses.

Authors:  Christina Prescott; Autumn M Weeks; Kevin J Staley; Kathryn M Partin
Journal:  Neurosci Lett       Date:  2006-04-27       Impact factor: 3.046

3.  Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Authors:  Daniel Zwilling; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Paolo Guidetti; Hui-Qiu Wu; Jason Lee; Jennifer Truong; Yaisa Andrews-Zwilling; Eric W Hsieh; Jamie Y Louie; Tiffany Wu; Kimberly Scearce-Levie; Christina Patrick; Anthony Adame; Flaviano Giorgini; Saliha Moussaoui; Grit Laue; Arash Rassoulpour; Gunnar Flik; Yadong Huang; Joseph M Muchowski; Eliezer Masliah; Robert Schwarcz; Paul J Muchowski
Journal:  Cell       Date:  2011-06-10       Impact factor: 41.582

4.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

Authors:  M N Perkins; T W Stone
Journal:  Brain Res       Date:  1982-09-09       Impact factor: 3.252

Review 5.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

6.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Modifications on the carboxylic function of kynurenic acid.

Authors:  Ferenc Fülöp; István Szatmári; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-10-14       Impact factor: 3.575

Review 8.  Pharmacological approaches to improve endothelial repair mechanisms.

Authors:  Christian Besler; Carola Doerries; Giovanna Giannotti; Thomas F Lüscher; Ulf Landmesser
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-09

9.  Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor.

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Jolanta Parada-Turska; Barbara Zdzisinska; Robert Rejdak; Tomasz Kocki; Etsuo Okuno; Martyna Kandefer-Szerszen; Eberhart Zrenner; Waldemar A Turski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-10       Impact factor: 3.000

10.  Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions.

Authors:  Marita C Barth; Neil Ahluwalia; Thomas J T Anderson; Gregory J Hardy; Sumita Sinha; Jose A Alvarez-Cardona; Ivy E Pruitt; Eugene P Rhee; Richard A Colvin; Robert E Gerszten
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

View more
  2 in total

1.  Effective Activation by Kynurenic Acid and Its Aminoalkylated Derivatives on M-Type K+ Current.

Authors:  Yi-Ching Lo; Chih-Lung Lin; Wei-Yu Fang; Bálint Lőrinczi; István Szatmári; Wan-Hsuan Chang; Ferenc Fülöp; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

2.  Rac1/Wave2/Arp3 Pathway Mediates Rat Blood-Brain Barrier Dysfunction under Simulated Microgravity Based on Proteomics Strategy.

Authors:  Ranran Yan; Huayan Liu; Fang Lv; Yulin Deng; Yujuan Li
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.